Overview
In line with Singapore's National Artificial Intelligence (AI) Strategy, a study done in 2018 found that healthcare professionals in Singapore were found to be ranked third globally when it comes to using AI for clinical diagnosis. However, more healthcare innovators and practitioners are now pushing the limits to what AI in the healthcare industry can do. With the development of novel AI models for disease prediction and management, companies have shown that through innovation and collaboration, there is an opportunity for AI to be a useful tool in more ways than one.
One avenue that AI in healthcare has shown promise in is immunotherapy for cancer treatment. AI platforms have shown promise when it comes to site activation, rapid identification, as well as drug screening and discovery. With cancer cases rising over the years in Singapore and other countries around the world, such platforms could give healthcare professionals an edge in the global fight against cancer.
At this session, we look at how AI-powered solutions could be used to address major challenges in drug discovery and precision medicine. Join us at our event as we hear from industry experts on how the healthcare industry could leverage AI platforms in immunotherapy and how this could be a potential game-changer for cancer therapy.
Date: 18 February 2021
Time: 10:00am - 11:00am (Singapore Time / UTC +8)
Programme:
10:00am - 10:05am: Opening Remarks and Welcome by SGInnovate
10:05am - 11:00pm: Panel Discussion and Q&A on AI-Powered Solutions in Healthcare: A Precision Medicine Approach to Cancer Therapy
- Dr Konrad Paszkiewicz, Chief Technology Officer, Hummingbird Bioscience
- Chik Wai Chiew, Chief Executive Officer, Heritas Capital Management Pte Ltd
- Dr Shawn Hoon, Scientific Co-founder, Proteona
- Moderator:Lee Boon Kiat, Senior Manager, Singapore Economic Development Board (EDB)
Speakers' Profiles:
Dr Konrad Paszkiewicz, Chief Technology Officer, Hummingbird Bioscience
Konrad Paszkiewicz is the Chief Technology Officer of Hummingbird Bioscience and leads Hummingbird's internal platform technologies, including mAbPredict, omics-technologies, single-cell analysis, machine learning and infrastructure. Konrad has held several academic positions including Director of the Wellcome Trust Centre for Biomedical Informatics and the Genomics facility at the University of Exeter, UK.
Konrad's background is a blend of structural bioinformatics, genomics and data science. He is an author on over 45 peer-reviewed publications and an organizer and speaker at several renowned scientific workshops and seminar series. He holds an MSci in Physics and a PhD in Bioinformatics from Imperial College, London.
Chik Wai Chiew, Executive Director & CEO, Heritas Capital Management Pte Ltd
Wai Chiew is the Executive Director & CEO of Heritas Capital Management, a Singapore-based private equity and venture capital investor in healthcare, education and technology sectors across Asia Pacific.Heritas' healthcare portfolio investments include leading health-tech ventures throughout Asia such as Holmusk, Tessa Therapeutics, Hummingbird Bioscience, Alodoktor, Strand Life Sciences, MFine.
Wai Chiew has over 20 years of experience in global investment management and strategic business development, having served various roles in Temasek Holdings, A*Star, EDB, and World Economic Forum, etc. He also actively serves as a director on multiple boards to advocate sustainable growth and sound governance.
Wai Chiew was awarded the Glaxo-EDB scholarship and holds a BA in Economics from Cambridge University, UK; MA from Yale University, USA; and completed EMBA (conducted in Mandarin) from Cheung Kong Graduate School of Business, China.
Dr Shawn Hoon, Scientific Co-founder, Proteona
Shawn is the Director of the MolecularEngineering Laboratory at the Institute of Molecular and Cell Biology, A*STAR which he helped establish with Dr Sydney Brenner. The group comprises >20 multi-disciplinary scientists working at the intersection of engineering and life sciences. He is a trainedcomputer engineer and geneticist and has been involved with many large-scale genome projects ranging from the sequencing of the Fugu genome to chemical genomic profiling. He has published widely in the area of bioinformatics and next-generation sequencing. He is a co-founder of Proteona, a multi-omic single-cell companywhose goal is to improve clinical outcomes in the space of oncology. He holds a BSc from the University of Virginia in Electrical Engineering and a PhD from Stanford University in Genetics.
Moderator's Profile:Lee Boon Kiat, Senior Manager, Singapore Economic Development Board (EDB)
Boon Kiat is Senior Manager of the Healthcare and Wellness team at the Singapore Economic Development Board (EDB). He has been involved in the development of the Singapore Healthcare industry ever since joining the EDB in 2013.
Boon Kiat was responsible for engaging key Healthcare MNCs and local biotechs in expanding their operations in Singapore and was involved in the development of new programmes for the pharmaceutical sector, covering across manpower training, advanced manufacturing and life sciences research. He is currently working on the industry engagement strategy for the Singapore National Precision Medicine Programme.
Boon Kiat graduated from Imperial College London with a BSc in Chemistry.
